O
ORIC icon

OrbiMed’s Oric Pharmaceuticals ORIC Stock Holding History

OrbiMed’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.8M Sell
2,015,000
-678,929
-25% -$6.16M 0.4% 63
2026
Q1 		$34.1M Sell
2,693,929
-947,827
-26% -$10.8M 0.68% 44
2025
Q4 		$29.8M Hold
3,641,756
– – 0.61% 48
2025
Q3 		$43.7M Buy
3,641,756
+2,742,475
+305% +$28.9M 1.03% 33
2025
Q2 		$9.13M Buy
899,281
+199,281
+28% +$1.34M 0.23% 61
2025
Q1 		$3.91M Buy
+700,000
New +$6.12M 0.09% 83
2024
Q3 		– Sell
-287,100
Closed -$2.03M – 129
2024
Q2 		$2.03M Hold
287,100
– – 0.04% 105
2024
Q1 		$3.95M Sell
287,100
-235,868
-45% -$2.8M 0.07% 100
2023
Q4 		$4.81M Sell
522,968
-370,700
-41% -$2.68M 0.1% 90
2023
Q3 		$5.41M Sell
893,668
-274,800
-24% -$2.25M 0.11% 97
2023
Q2 		$9.07M Sell
1,168,468
-206,000
-15% -$1.17M 0.16% 92
2023
Q1 		$7.83M Sell
1,374,468
-233,100
-15% -$1.22M 0.15% 91
2022
Q4 		$9.47M Sell
1,607,568
-480,000
-23% -$1.62M 0.18% 77
2022
Q3 		$6.68M Hold
2,087,568
– – 0.12% 98
2022
Q2 		$9.35M Hold
2,087,568
– – 0.17% 93
2022
Q1 		$11.1M Sell
2,087,568
-250,006
-11% -$2.25M 0.18% 97
2021
Q4 		$34.4M Hold
2,337,574
– – 0.44% 62
2021
Q3 		$48.9M Hold
2,337,574
– – 0.54% 51
2021
Q2 		$41.4M Hold
2,337,574
– – 0.42% 65
2021
Q1 		$57.3M Sell
2,337,574
-584,393
-20% -$18.5M 0.54% 53
2020
Q4 		$98.9M Hold
2,921,967
– – 0.87% 33
2020
Q3 		$73.1M Hold
2,921,967
– – 0.92% 33
2020
Q2 		$98.6M Buy
+2,921,967
New +$93.3M 1.39% 23

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed's ORIC Position: Q2 2026 in Review

OrbiMed reduced its Oric Pharmaceuticals (ORIC) stake by 25% in Q2 2026, selling an estimated $6.16M and leaving 2,015,000 shares worth $21.8M. The position accounts for 0.4% of the portfolio, ranked #63.

OrbiMed first reported a position in ORIC in Q2 2020 and has held it in 23 quarters since. The position peaked at $98.9M in Q4 2020. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • OrbiMed held 2,015,000 shares of Oric Pharmaceuticals worth $21.8M as of Q2 2026.
  • OrbiMed sold 678,929 Oric Pharmaceuticals shares in Q2 2026, an estimated $6.16M.
  • Oric Pharmaceuticals made up 0.4% of OrbiMed's portfolio in Q2 2026, its #63 holding.
  • OrbiMed first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • OrbiMed's Oric Pharmaceuticals position peaked at $98.9M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.